IBM has formed a healthcare advisory board for its Watson computing system that includes Lynda Chin as a member. Chin is a professor and chair of the department of genomic medicine at the University of Texas MD Anderson Cancer Center. Chin is involved in the Cancer Genome Atlas and the International Cancer Genome Consortium. Previously she was scientific director of the Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute as well as a professor in the department of medical oncology at Dana-Farber and professor in the department of dermatology at Harvard Medical School. She holds an MD from Albert Einstein College of Medicine.
Complete Genomics has formed a genomic medicine advisory board. Robert Nussbaum will serve as chairman. He is currently chief of the division of genetics in the department of medicine and director of the Cancer Risk and Cardiovascular Genetics Programs at the University of California, San Francisco.
Other members include Jonathan Berg, assistant professor in the department of genetics at the University of North Carolina; Charis Eng, chair and director of the Genomic Medicine Institute at the Cleveland Clinic; Brynn Levy, associate professor of clinical pathology and cell biology and co-director of the division of personalized genomic medicine at the College of Physicians and Surgeons of Columbia University and director of the clinical cytogenetics laboratory at the New York Presbyterian Hospital at Columbia University Medical Center; Elaine Lyon, associate professor of pathology at the University of Utah School of Medicine and medical director of the genetics division, and co-medical director of pharmacogenomics at Arup Laboratories; Federico Monzon, associate professor of pathology and immunology and director of molecular pathology at the Cancer Genetics Laboratory at Baylor College of Medicine; DesiRae Muirhead, assistant professor of pathology at Sanford School of Medicine at the University of South Dakota; Sterling Puck, former vice president for medical affairs at Genzyme Genetics; and Heidi Rehm, director of the Laboratory for Molecular Medicine at Partners HealthCare Center for Personalized Genetic Medicine and assistant professor of pathology at Harvard Medical School.